Mobile navigation
Tests
Tests for Providers
Clinical Tests
Discover
Connect With Us
Tests for Patients
Cancer Tests
Learn
Need Help?
Resources
Resources for Providers
Resource Centers
Explore
Resources for Patients
Innovation
Technology
Research Use Only
Company
About Us
News & Events
Connect
Investors
Welcome
Financials
Governance
Investor Resources
Search
Explore our portfolio of market-leading molecular tests and pipeline innovations helping to transform cancer care for patients worldwide.
Click on the various phases to discover our platform solutions.
Helix® for Decipher Prostate
Percepta Nasal Swab Test
Afirma Genomic Sequencing Classifier
Decipher Bladder Genomic Classifier
Decipher Prostate Genomic Classifier
Prosigna Breast Risk of Recurrence Test
Prosigna Breast Cancer Assay
TrueMRD Monitoring Test for Muscle-Invasive Bladder Cancer
Filter By
Helps clinicians personalize thyroid cancer diagnosis and treatment decisions for their patients with thyroid nodules.
Cancer Journey Stage:
Test Type:
Sample Type:
Availability:
Test Extensions:
DNA TERTp Analysis Determines TERT promoter gene mutation status to help further personalize diagnosis and treatment for patients with thyroid nodules that are suspicious for cancer.
Research-Use-Only:
Afirma GRID Proprietary research-use-only database designed to help clinicians advance the understanding of managing patients with thyroid nodules and thyroid cancer.
Helps inform personalized treatment decisions in bladder cancer by revealing underlying tumor biology.
Decipher Bladder GRID Proprietary research-use-only database designed to help clinicians advance the understanding of bladder cancer at the molecular level.
Helps inform treatment decisions by assessing risk of metastasis or metastatic progression for men with localized or advanced prostate cancer.
Advanced and Metastatic Tumors Intended to expand the Decipher Prostate test coverage to advanced and metastatic prostate tumors.
Helix® Integrates whole-exome hereditary testing with Decipher Prostate to reveal both inherited risk and tumor biology.
Decipher Prostate GRID Proprietary research-use-only database designed to help clinicians advance the understanding of prostate cancer at the molecular level.
For patients in the United States. Informs treatment decisions for women with early-stage breast cancer.
For patients outside of the United States. Informs treatment decisions for women with early-stage breast cancer.
Intended for minimal residual disease (MRD) assessment for patients with muscle-invasive bladder cancer (MIBC).
No results for the selected filters.
Uses a simple, non-invasive nasal brushing to objectively assess cancer risk in lung nodules found on computed tomography (CT) scans.
Disease Area:
Cancer Care Stage:
A novel diagnostics platform helping unlock deeper cancer insights.
Studies demonstrating the impact of our tests across cancer types.
Veracyte publications and references showcasing discoveries and advancements.
New data, partner announcements, and financial reports.
Need help or have questions about our technology?
This webpage contains forward-looking statements. These forward-looking statements involve risks and uncertainties. For more information, read our full Forward-Looking Statements disclosure.
Afirma testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required. Afirma tests may be available outside the US in select instances.
Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.
Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.
The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as a CE-IVD test outside the US.
Talk to your doctor about whether Veracyte tests might be right for you.